Intercept Pharmaceuticals CEO Mark Pruzanski's 2018 pay falls 26% to $4.5M
Intercept Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 30, 2019
Intercept Pharmaceuticals reported fiscal year 2018 executive compensation information on April 30, 2019.
In 2018, five executives at Intercept Pharmaceuticals received on average a compensation package of $3M, a 7% decrease compared to previous year.
Average pay of disclosed executives at Intercept Pharmaceuticals
Mark Pruzanski, Chief Executive Officer, received $4.5M in total, which decreased by 26% compared to 2017. 38% of Pruzanski's compensation, or $1.7M, was in option awards. Pruzanski also received $442K in non-equity incentive plan, $702K in salary, $1.7M in stock awards, as well as $8.6K in other compensation.
For fiscal year 2018, the median employee pay was $244,883 at Intercept Pharmaceuticals. Therefore, the ratio of Mark Pruzanski's pay to the median employee pay was 18 to one.
Ryan Sullivan, General Counsel, received a compensation package of $3.2M. 39% of the compensation package, or $1.2M, was in stock awards.
Jerome Durso, Chief Operating Officer, earned $3.2M in 2018, a 18% decrease compared to previous year.
Gail Cawkwell, SVP, Medical Affairs, Safety & Pharmacovigilance, received $2.2M in 2018.
Sandip Kapadia, Chief Financial Officer, earned $1.9M in 2018, a 12% decrease compared to previous year.
Related executives
Mark Pruzanski
Intercept Pharmaceuticals
Chief Executive Officer
Sandip Kapadia
Intercept Pharmaceuticals
Chief Financial Officer
Jerome Durso
Intercept Pharmaceuticals
Chief Executive Officer
Ryan Sullivan
Intercept Pharmaceuticals
General Counsel
Gail Cawkwell
Intercept Pharmaceuticals
SVP Medical Affairs, Safety & Pharmacovigilance
You may also like
Source: SEC filing on April 30, 2019.